2015;33(34):4066-76. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20.Lichtenegger FS, Krupka C, Haubner S, et al. Recent developments in immunotherapy of acute myeloid leukemia. J Hematol Oncol. 2017;10:142 . Lim D, Murali R, Murray MP, et al. Morphological and immunohistochemical reevaluation of tumors initially diagnosed as ovarian endometrioid carcinoma with emphasis on high - grade tumors. Am J Surg Pathol. 2016;40:302-12. Lindstedt I, Lindgren MA, Andersson E, et al. The WT1 gene--its role in tumourigenesis and prospects for immunotherapeutic advances. In Vivo. 2014;28:675-81. Link JT, Overman MJ. Immunotherapy progress in mismatch repair -deficient colorectal cancer and future therapeutic challenges. Cancer J. 2016;22:190 -5. Lowenberg B, Ossenkopple GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med.